Sector
1090 stories · page 40 of 55
To date, the company said IRP has successfully performed over 10,000 unique treatments for past or present personnel of the Canadian Armed Forces and the Royal Canadian Mounted Police (RCMP), as well as first responders including firefighte
Analysts were impressed with CareRx's 3Q revenue of C$71.3 million, which beat estimates and led to a series of increased price targets
Through its Bioscience lab, Numinus is the first public company in Canada to receive a licence to produce and extract psilocybin from mushrooms
For the period ended September 30, 2021, the Toronto-based company reported revenue of C$71.3 million, compared to C$45.6 million in the corresponding period a year earlier
KetaMD, currently in beta, is a telemedicine platform in development that aims to provide affordable, potentially life-changing at-home medical ketamine treatments guided by registered nurses
The company also said that it has appointed Director Steven Inglefield as Chief Operating Officer as the company continues to grow its clinic network across Canada and the US
The company expects its Software-as-a-Service (SaaS) revenue for fiscal 2021 to increase by more than 100% year over year
The company is working swiftly to establish itself as a leader in the integrated wellness and psychedelic medicine market
Under the partnership with iHealthOX, patients will have the option of being virtually assessed by a physician and a clinical health provider to determine their suitability to undergo ketamine therapy
The prevalence of infection is 1.72%, compared with 0.83% in September
Through this program, therapists will be competent to perform psilocybin-assisted therapy in upcoming clinical trials, evaluating the safety and efficacy of psilocybin in depression
It is developing a ready-to-administer product for a leading global medical products company
The initial commercialization efforts will focus on the aviation, healthcare, mining, and construction sectors, where workers are at heightened risk of excessive sleepiness at work and insomnia at home
The firm intends to enter the North American cannabis industry by licensing its household brand name to licensed third parties that manufacture products containing tetrahydrocannabinol (THC)
Ketamine One is also working with OTC markets and other applicable regulatory agencies to become ‘15c2-11 Certified’ under Rule 15c2-11 of the Securities and Exchange Commission of the United States
The license agreement centers on sleep chronotype assessments and educational content
The study, titled ‘Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction’, suggests public policies and strategies for reducing suicide rates in the country
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
The observational studies will collect advanced biometric data in upcoming depression and post-traumatic stress disorder studies across locations in Canada and the US
The Wonderland: Miami conference is scheduled to kick off on November 8, inviting multiple companies in the psychedelic space to connect with the psychedelic medicinal space
